A biopharmaceutical company has launched a pilot study testing a GLP-1 drug implant for obese cats, potentially bringing the weight-loss drug trend to pets. Okava Pharmaceuticals, based in San Francisco, is expected to announce the study on Tuesday, according to the New York Times.
Unlike the weekly injections of Ozempic, Wegovy, or Mounjaro used by humans, the cats in Okava’s study will receive a small implant under the skin, slightly larger than a microchip. The device releases medication slowly over up to six months, offering a low-maintenance option to address rising pet obesity rates.
Pet owners’ awareness of weight issues is growing. In 2024, only 55% of cat owners and 51% of dog owners reported their pets had an ideal body condition, down from 2023, according to the Association for Pet Obesity Prevention. Meanwhile, 33% of cat owners and 35% of dog owners recognised their pets as overweight or obese, up from 28% and 17% respectively the previous year.
Okava aims to price the implant at $100 (£80) per month or less, comparable to high-end pet food, and potentially saving owners money by preventing or managing diabetes. However, some experts note that feeding pets is a primary way owners show affection, and older appetite-suppressing drugs like Slentrol were unpopular for that reason.
Dr Chen Gilor, a veterinarian at the University of Florida leading the study, called the implant “magic”, highlighting that diabetes in cats is treatable but often poorly managed. Results are expected next summer, and if successful, the study could open a new frontier for GLP-1 drugs in veterinary care.
